The kinetics of change in cytokine production by CD4+ T cells during conventional allergen immunotherapy

Journal of Allergy and Clinical Immunology

Volumn 103, Issue 3 II, 1999, Pages 468-475

  Benjaponpitak, Suwat ^a   Oro, Amy ^a   Maguire, Peter ^a   Marinkovich, Vince ^b   DeKruyff, Rosemarie H ^a   Umetsu, Dale T ^a  

^a STANFORD UNIVERSITY   (United States)

^b MAST Immunosystems   (United States)

Author keywords

Allergen desensitization; Allergy; Desensitization; IL 4; Immunotherapy

Indexed keywords

ALLERGEN; CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HISTAMINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 4; POLLEN ANTIGEN; TETANUS TOXOID;

ADULT; ALLERGY; ANTIGEN PRESENTING CELL; ARTICLE; ASTHMA; CLINICAL ARTICLE; DESENSITIZATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADULT; ALLERGENS; ANTIBODY SPECIFICITY; ANTIGENS, DERMATOPHAGOIDES; CD4-POSITIVE T-LYMPHOCYTES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN E; INTERFERON TYPE II; INTERLEUKIN-4; KINETICS; MALE; MIDDLE AGED; POLLEN; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 0033016327     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70473-2     Document Type: Article

References (38)

1. Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immu no therapy: a single year double blind placebo controlled study in patients with grass pollen induced asthma and rhinitis. J Allergy Clin Immunol 1984;73:283-90.
2. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis. Comparing clinical out-come with antigen specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990;86:521-31.
3. Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986;78:590-600.
4. Bousquet J, Hejjiaout A, Clauzel A-M, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:971-7.
5. Joint Task Force on Practice Parameters. Practice parameters for allergen immunotherapy. J Allergy Clin Immunol 1996;98:1001-11.
6. + T cells from allergic individuals. J Exp Med 1993;178:2123-30.
7. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-94.
8. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644-51.
9. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989;7:145-73.
10. Umetsu DT, Jabara HH, DeKruyff RH, Abbas AK, Abrams JS, Geha RS. Functional heterogeneity among human inducer T cell clones. J Immunol 1988;140:4211-6.
11. + T lymphocytes in atopic patients. J Immunol 1990;144:4651-6.
12. Akoum H, Tsicopoulos A, Vorng H, et al. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes. Immunology 1996;87:593-8.
13. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995;25:828-38.
14. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-9.
15. + T cells requires repeated antigenic stimulation. Cell Immunol 1993;152:18-34.
16. Bird JJ, Brown DR, Mullen AC, et al. Helper T cell differentiation is controlled by the cell cycle. Immunity 1998;9:229-37.
17. Weinberg AD, English M, Swain SL. Distinct regulation of lymphokine production is found in fresh versus in vitro primed helper T cells. J Immunol 1990;144:1800-7.
18. Kullberg MC, Pearce EJ, Hieny SE, Sher A, Berzofsky JA. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J Immunol 1992;148:3264-70.
19. Norman PS. Modern concepts of immunotherapy. Curr Opin Immunol 1993;5:968-73.
20. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157-64.
21. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996;97:1356-65.
22. O'Brien RM, Byron KA, Varigos GA, Thomas WR. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-gamma and IL-4 expression by circulating T lymphocytes. Clin Exp Allergy 1997;27:46-51.
23. Soderlund A, Gabrielsson S, Paulie S, Hammarstrom ML, Rak S, Troye-Blomberg M. Allergen induced cytokine profiles in type I allergic individuals before and after immunotherapy. Immunol Lett 1997;57:177-81.
24. Peng ZK, Naclerio RM, Norman PS, Adkinson NF Jr. Quantitative IgE- and IgG-subclass responses during and after long-term ragweed immunotherapy. J Allergy Clin Immunol 1992;89:519-29.
25. Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J Allergy Clin Immunol 1981;68:460-70.
26. Kabelitz D, Pohl T, Pechold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993;14:338-9.
27. Critchfield JM, Lenardo MJ. Antigen-induced programmed T cell death as a new approach to immune therapy. Clin Immunol Immunopathol 1995;75:13-9.
28. Akdis CA, Akdis M, Blesken T, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676-83.
29. Hoekstra MO, Hoekstra Y, Reus D, Rutgers B, Gerritsen J, Kauffman HF. Interleukin-4, interferon-γ and interleukin-5 in peripheral blood of children with moderate atopic asthma. Clin Exp Allergy 1997;27:1254-60.
30. + lymphocytes by inhibiting IL-12 production. J Immunol 1998;160:2231-7.
31. Tamada K, Harada M, Abe K, Li T, Nomoto K. IL-4-producing NK1.1+ T cells are resistant to glucocorticoid-induced apoptosis: implications for the Th1/Th2 balance. J Immunol 1998;161:1239-47.
32. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998;161:2586-93.
33. Nagaya H. Induction of antigen-specific suppressor cells in patients with hay fever receiving immunotherapy. J Allergy Clin Immunol 1985;75:388-94.
34. McMenamin C, Holt PG. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993;178:889-99.
35. Kim TS, DeKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol 1997;158:4137-44.
36. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. Vaccine 1997;15:1687-96.
37. Raz E, Tighe H, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci 1996;93:5141-5.
38. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nature Medicine 1996;2:540-4.